Key Insights

Highlights

Success Rate

84% trial completion

Published Results

24 trials with published results (12%)

Research Maturity

109 completed trials (54% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

9.9%

20 terminated out of 202 trials

Success Rate

84.5%

-2.0% vs benchmark

Late-Stage Pipeline

19%

38 trials in Phase 3/4

Results Transparency

22%

24 of 109 completed with results

Key Signals

24 with results84% success20 terminated

Data Visualizations

Phase Distribution

142Total
Not Applicable (72)
Early P 1 (1)
P 1 (20)
P 2 (11)
P 3 (12)
P 4 (26)

Trial Status

Completed109
Unknown31
Recruiting23
Terminated20
Withdrawn8
Active Not Recruiting5

Trial Success Rate

84.5%

Benchmark: 86.5%

Based on 109 completed trials

Clinical Trials (202)

Showing 20 of 20 trials
NCT07227506RecruitingPrimary

Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:

NCT07716592Not ApplicableNot Yet RecruitingPrimary

PROPER-GERD: A Prospective Crossover Study to Evaluate Probe Placement Optimization for Reflux Testing in Women and Lower-BMI Patients

NCT07310927Phase 2CompletedPrimary

Alginate vs Sucralfate for GERD Symptomatic Relief

NCT03886961Not ApplicableRecruiting

The Effect of the Reflux Band™ Upper Esophageal Sphincter (UES) Assist Device on Reflux for Lung Transplant Recipients

NCT07659080Not ApplicableNot Yet RecruitingPrimary

Antireflux Surgery Without Preoperative Esophageal Manometry

NCT03705416Active Not RecruitingPrimary

Long Term Outcomes of Bariatric Patients Treated With Surgery or Endoscopy

NCT05469854Phase 1Recruiting

A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate

NCT07634614Enrolling By InvitationPrimary

Pre- and Post-Therapy Evaluation of Air-Associated Symptoms in Patients With Gastro-esophageal Reflux Disease (GERD): Assessing the Role of Speech and Language Therapy

NCT04248335Phase 4Completed

Effect of Obesity on Proton Pump Inhibitors

NCT06241183Phase 4Recruiting

Famotidine and Antacids for Treatment of Dyspepsia

NCT02441400TerminatedPrimary

EndoStim Patient Registry

NCT07556289Phase 2Recruiting

Transoral Incisional Fundoplication (TIF) for Patients Suffering From Gastroesophageal Reflux Disease in an Asian Population

NCT06955520Not ApplicableRecruitingPrimary

Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM

NCT07544433Not ApplicableRecruitingPrimary

Diaphragmatic Training on GERD

NCT07506746Recruiting

PRospective Registry of Esophageal Motility

NCT04699591Not ApplicableRecruitingPrimary

Compassionate Use of Domperidone for Refractory Gastroparesis

NCT06953986Not ApplicableRecruitingPrimary

A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks

NCT07421011Phase 1Recruiting

Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

NCT05696184Not ApplicableRecruitingPrimary

Mechanisms Preventing Pharyngeal Reflux

NCT01799967Active Not Recruiting

Minimally Invasive Surgery of the Gastro-esophageal Junction

Scroll to load more

Research Network

Activity Timeline